Navigation Links
Alaska graduate program in sustainability receives $3.2 million award
Date:10/18/2007

FAIRBANKS, Alaska Graduate students and scientists of the Resilience and Adaptation Program at the University of Alaska Fairbanks received a five-year, $3.2 million grant from the National Science Foundation to address questions of social-ecological resilience, adaptation and sustainability.

RAP focuses on answering questions of how global processes, like climate change, affect local processes, such as indigenous subsistence hunting. Economic, cultural and ecological dimensions of sustainability have to be considered together. To do that requires an integrated science that draws on several disciplinary perspectives, said Gary Kofinas, RAP director and UAF associate professor of resource policy and management.

RAP is a graduate program that uses an innovative team-taught curriculum, hands-on internships and problem-centered training. Students from traditional disciplines such as economics, anthropology, political science and biology address issues of global-local sustainability in an integrated and interdisciplinary fashion.

Sustainability means that society has to think carefully about how the choices it makes now will affect the worlds ability to retain the characteristics society wants to hold onto, said Kofinas. Student projects have included green consumerism, arctic militarization, carbon sequestration, cancer and persistent waste, co-management of marine mammals, and the road ecology of caribou.

The grant is RAPs second from NSF and will support 25 two-year traineeships for participating PhD students. This dedicated time allows students to focus on their research, work with their advisors, secure research dollars to finish their projects, and complete their dissertation, said Kofinas.

RAP, which is funded through the Institute of Arctic Biology, is one of more than 120 NSF Integrative Graduate Education and Research Traineeships in the United States, and regarding as one of the most successful programs. On
'/>"/>

Contact: Marie Gilbert
marie.gilbert@uaf.edu
907-474-7412
University of Alaska Fairbanks
Source:Eurekalert

Page: 1 2

Related biology news :

1. Alaskan puzzles, monitoring provide insight about North Pacific salmon runs
2. Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska
3. Lands surface change on Alaska tundra creating longer, warmer summers in Arctic
4. On a wing and a prayer - Alaska researchers seek clues to bird flu
5. Alaska seal pup diet may hold key to decline of population
6. NASA study: Alaskan fires affected Houston air quality in 2004
7. Shrinking ponds signal warmer, dryer Alaska
8. Ice Age extinction claimed highly carnivorous Alaskan wolves
9. Undergraduate research shows leaderless honeybee organizing
10. Critical role in programmed cell death identified
11. Applied Biosystems Introduces Advanced Gene Expression Service Provider Program
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3